317 related articles for article (PubMed ID: 22019587)
1. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
Horikawa M; Minard-Colin V; Matsushita T; Tedder TF
J Clin Invest; 2011 Nov; 121(11):4268-80. PubMed ID: 22019587
[TBL] [Abstract][Full Text] [Related]
2. Regulatory B cell (B10 Cell) expansion during Listeria infection governs innate and cellular immune responses in mice.
Horikawa M; Weimer ET; DiLillo DJ; Venturi GM; Spolski R; Leonard WJ; Heise MT; Tedder TF
J Immunol; 2013 Feb; 190(3):1158-68. PubMed ID: 23275601
[TBL] [Abstract][Full Text] [Related]
3. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Tedder TF; Baras A; Xiu Y
Springer Semin Immunopathol; 2006 Dec; 28(4):351-64. PubMed ID: 17091246
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
Minard-Colin V; Xiu Y; Poe JC; Horikawa M; Magro CM; Hamaguchi Y; Haas KM; Tedder TF
Blood; 2008 Aug; 112(4):1205-13. PubMed ID: 18495955
[TBL] [Abstract][Full Text] [Related]
5. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.
Hamaguchi Y; Uchida J; Cain DW; Venturi GM; Poe JC; Haas KM; Tedder TF
J Immunol; 2005 Apr; 174(7):4389-99. PubMed ID: 15778404
[TBL] [Abstract][Full Text] [Related]
6. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
7. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
8. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
9. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
Uchida J; Hamaguchi Y; Oliver JA; Ravetch JV; Poe JC; Haas KM; Tedder TF
J Exp Med; 2004 Jun; 199(12):1659-69. PubMed ID: 15210744
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
Bhatt S; Parvin S; Zhang Y; Cho HM; Kunkalla K; Vega F; Timmerman JM; Shin SU; Rosenblatt JD; Lossos IS
Blood; 2017 Apr; 129(16):2246-2256. PubMed ID: 28137826
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.
DiLillo DJ; Hamaguchi Y; Ueda Y; Yang K; Uchida J; Haas KM; Kelsoe G; Tedder TF
J Immunol; 2008 Jan; 180(1):361-71. PubMed ID: 18097037
[TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
Hamaguchi Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
14. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
[TBL] [Abstract][Full Text] [Related]
15. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.
Yoshizaki A; Miyagaki T; DiLillo DJ; Matsushita T; Horikawa M; Kountikov EI; Spolski R; Poe JC; Leonard WJ; Tedder TF
Nature; 2012 Nov; 491(7423):264-8. PubMed ID: 23064231
[TBL] [Abstract][Full Text] [Related]
16. Blimp-1 Contributes to the Development and Function of Regulatory B Cells.
Wang YH; Tsai DY; Ko YA; Yang TT; Lin IY; Hung KH; Lin KI
Front Immunol; 2019; 10():1909. PubMed ID: 31474988
[TBL] [Abstract][Full Text] [Related]
17. TLR9 mediated regulatory B10 cell amplification following sub-total body irradiation: Implications in attenuating EAE.
Hong J; Fang J; Lan R; Tan Q; Tian Y; Zhang M; Okunieff P; Zhang L; Lin J; Han D
Mol Immunol; 2017 Mar; 83():52-61. PubMed ID: 28110075
[TBL] [Abstract][Full Text] [Related]
18. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
19. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.
Matsushita T; Yanaba K; Bouaziz JD; Fujimoto M; Tedder TF
J Clin Invest; 2008 Oct; 118(10):3420-30. PubMed ID: 18802481
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
Taylor RP; Lindorfer MA
Curr Opin Immunol; 2008 Aug; 20(4):444-9. PubMed ID: 18585457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
